Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

INTRODUCTION: Immune checkpoint inhibitors (ICIs) enhance the immune system’s ability to target and destroy cancer cells, but this non-specific immune overactivation can result in immune-related adverse events (irAEs). Patients with underlying autoimmune diseases were excluded from the original ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Lusa, Amanda, Alvarez, Carolina, Saxena Beem, Shruti, Schwartz, Todd A., Ishizawar, Rumey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641936/
https://www.ncbi.nlm.nih.gov/pubmed/36345032
http://dx.doi.org/10.1186/s41927-022-00297-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641936/
https://www.ncbi.nlm.nih.gov/pubmed/36345032
http://dx.doi.org/10.1186/s41927-022-00297-5

Ejemplares similares